Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Price:
30.83 USD
1.85%
Market Closed
Updated:
May 6, 2024
Supernus Pharmaceuticals Inc
Net Income (Common)
|
Supernus Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
Net Income (Common)
$1.3m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$38.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
-$309m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
See Also
What is Supernus Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
1.3m
USD
1.3m
USD
Based on the financial report for Dec 31, 2023, Supernus Pharmaceuticals Inc's Net Income (Common) amounts to 1.3m USD.
What is Supernus Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-59%
-59%
Over the last year, the Net Income (Common) growth was -98%. The average annual Net Income (Common) growth rates for Supernus Pharmaceuticals Inc have been -78% over the past three years , -59% over the past five years .
You don't have any saved screeners yet
